Aaron Elliott Lisberg

Title(s)HS Assistant Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
    NIH K08CA245249Jul 1, 2020 - Jun 30, 2025
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Mar 11; 125:102720. Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. PMID: 38502995.
      View in: PubMed   Mentions:    Fields:    
    2. Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors? J Thorac Oncol. 2023 09; 18(9):e97-e99. Lee ATM, Ou SI, Lisberg A. PMID: 37599056.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. J Immunother Cancer. 2023 09; 11(9). Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Ling Huang Z, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, Abascal J, Seet C, Oh M, Shabihkhani M, Paul M, Krysan K, Lisberg AE, Garon EB, Liu B, Dubinett SM. PMID: 37730274; PMCID: PMC10510892.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    4. Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection. J Thorac Oncol. 2023 09; 18(9):1129-1133. Moghanaki D, Lisberg A, Oh S, Lee JM. PMID: 37599046.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Consent document translation expense hinders inclusive clinical trial enrolment. Nature. 2023 Aug; 620(7975):855-862. Velez MA, Glenn BA, Garcia-Jimenez M, Cummings AL, Lisberg A, Nañez A, Radwan Y, Lind-Lebuffe JP, Brodrick PM, Li DY, Fernandez-Turizo MJ, Gower A, Lindenbaum M, Hegde M, Brook J, Grogan T, Elashoff D, Teitell MA, Garon EB. PMID: 37532930.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records. J Immunother Cancer. 2023 08; 11(8). Beaufils M, Amodru V, Tejeda M, Boher JM, Zemmour C, Chanez B, Chrétien AS, Gorvel L, Gravis G, Bruyat D, Mari R, Madroszyk A, Cuny T, Gonçalves A, Lisberg AE, Olive D, Tassy L, Castinetti F, Rochigneux P. PMID: 37536938; PMCID: PMC10401250.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors. J Thorac Oncol. 2023 07; 18(7):847-850. Nadres B, Momcilovic M, Shackelford DB, Lisberg A. PMID: 37348993.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. J Clin Oncol. 2023 10 10; 41(29):4678-4687. Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, Greenberg J, Kawasaki Y, Zebger-Gong H, Kobayashi F, Phillips P, Lisberg AE, Heist RS. PMID: 37327461; PMCID: PMC10564307.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    9. Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 09 01; 117(1):118-122. Wu TC, Stube A, Felix C, Oseguera D, Romero T, Goldman J, Garon EB, Lee JM, Glaspy J, Lisberg AE, Rusthoven CG, Camidge DR, Siva S, Solomon B, Lee A, Tenn SE, Shaverdian N, Steinberg ML, Raldow AC, Lee P. PMID: 37023987.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    10. Spatial mapping of mitochondrial networks and bioenergetics in lung cancer. Nature. 2023 03; 615(7953):712-719. Han M, Bushong EA, Segawa M, Tiard A, Wong A, Brady MR, Momcilovic M, Wolf DM, Zhang R, Petcherski A, Madany M, Xu S, Lee JT, Poyurovsky MV, Olszewski K, Holloway T, Gomez A, John MS, Dubinett SM, Koehler CM, Shirihai OS, Stiles L, Lisberg A, Soatto S, Sadeghi S, Ellisman MH, Shackelford DB. PMID: 36922590; PMCID: PMC10033418.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    11. Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. JTO Clin Res Rep. 2023 Mar; 4(3):100468. Smith CP, Xiang M, Yoon SM, Lee A, Ruan D, Goldman JW, Cummings AL, Lisberg A, Garon EB, Moghanaki D. PMID: 36923158; PMCID: PMC10009282.
      View in: PubMed   Mentions: 1  
    12. Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. Clin Cancer Res. 2022 12 01; 28(23):5136-5148. Rochigneux P, Lisberg A, Garcia A, Granjeaud S, Madroszyk A, Fattori S, Gonçalves A, Devillier R, Maby P, Salem N, Gorvel L, Chanez B, Gukasyan J, Carroll J, Goldman J, Chretien AS, Olive D, Garon EB. PMID: 36166003; PMCID: PMC10085054.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    13. What is the current role of immunotherapy in EGFR mutant advanced NSCLC? Lung Cancer. 2022 04; 166:253-254. Velez MA, Tsai HHC, Shackelford DB, Garon EB, Lisberg A. PMID: 35031176.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC. JTO Clin Res Rep. 2021 Nov; 2(11):100242. Shahrouki P, Lee JM, Barclay J, Khan SN, Genshaft S, Abtin F, Dubinett SM, Lisberg A, Sharma S, Garon EB, Suh R. PMID: 34806054; PMCID: PMC8581369.
      View in: PubMed   Mentions:
    15. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer. 2021 11; 161:34-41. Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, Yessuf NM, Rettinger S, Grogan T, Rochigneux P, Goldman JW, Garon EB, Lisberg A. PMID: 34507111; PMCID: PMC8923054.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    16. Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs: Endorsed by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology. J Vasc Interv Radiol. 2021 Aug; 32(8):1241.e1-1241.e12. Genshaft SJ, Suh RD, Abtin F, Baerlocher MO, Chang AJ, Dariushnia SR, Devane AM, Faintuch S, Himes EA, Lisberg A, Padia S, Patel S, Tam AL, Yanagawa J. PMID: 34332724.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    17. Society of Interventional Radiology Quality Improvement Standards on Percutaneous Ablation of Non-Small Cell Lung Cancer and Metastatic Disease to the Lungs. J Vasc Interv Radiol. 2021 Aug; 32(8):1242.e1-1242.e10. Genshaft SJ, Suh RD, Abtin F, Baerlocher MO, Dariushnia SR, Devane AM, Himes E, Lisberg A, Padia S, Patel S, Yanagawa J. PMID: 34000388.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    18. Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. Nat Cancer. 2020 12; 1(12):1167-1175. Cummings AL, Gukasyan J, Lu HY, Grogan T, Sunga G, Fares CM, Hornstein N, Zaretsky J, Carroll J, Bachrach B, Akingbemi WO, Li D, Noor Z, Lisberg A, Goldman JW, Elashoff D, Bui AAT, Ribas A, Dubinett SM, Rossetti M, Garon EB. PMID: 35121931.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    19. Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. J Natl Compr Canc Netw. 2020 09; 18(9):1287-1290. Zhou N, Velez MA, Owen D, Lisberg AE. PMID: 32886906.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019 08 01; 30(8):1311-1320. Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. PMID: 31086949; PMCID: PMC6683857.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    21. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 08 15; 25(16):5061-5068. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. PMID: 31113840; PMCID: PMC6901027.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    22. Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. Transl Lung Cancer Res. 2019 Apr; 8(2):195-197. Lisberg A, Garon EB. PMID: 31106131; PMCID: PMC6504648.
      View in: PubMed   Mentions: 2  
    23. Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer? J Clin Oncol. 2019 03 01; 37(7):529-536. Lisberg A, Garon EB. PMID: 30676857.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    24. The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. J Thorac Oncol. 2018 08; 13(8):1058-1059. Lisberg A, Garon EB. PMID: 30056858.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018 08; 13(8):1138-1145. Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. PMID: 29874546; PMCID: PMC6063769.
      View in: PubMed   Mentions: 237     Fields:    Translation:HumansCTClinical Trials
    26. High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. J Thorac Dis. 2018 Feb; 10(Suppl 3):S397-S403. Ellis-Caleo T, Lisberg A, Tucker DA, Garon EB. PMID: 29593885; PMCID: PMC5861271.
      View in: PubMed   Mentions: 1  
    27. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunol Res. 2018 03; 6(3):288-294. Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. PMID: 29382669; PMCID: PMC6066474.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    28. Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. Transl Lung Cancer Res. 2017 Dec; 6(Suppl 1):S39-S40. Lisberg A, Garon EB. PMID: 29299407; PMCID: PMC5750165.
      View in: PubMed   Mentions: 5  
    29. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer. 2017 Dec 15; 123(24):4800-4807. Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB. PMID: 29125624; PMCID: PMC6263029.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    30. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 07; 18(7):895-903. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. PMID: 28551359; PMCID: PMC5538772.
      View in: PubMed   Mentions: 493     Fields:    Translation:HumansCTClinical Trials
    31. Mathematical modeling of the effects of CK2.3 on mineralization in osteoporotic bone. CPT Pharmacometrics Syst Pharmacol. 2017 03; 6(3):208-215. Lisberg A, Ellis R, Nicholson K, Moku P, Swarup A, Dhurjati P, Nohe A. PMID: 28181418; PMCID: PMC5351412.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer. 2017 04 15; 123(8):1464-1474. Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P. PMID: 27925665; PMCID: PMC5384867.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansPHPublic Health
    33. The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 May 01; 2(5):571-572. Lisberg A, Garon EB. PMID: 26986923.
      View in: PubMed   Mentions: 8     Fields:    
    34. Epigenetic regulation of the cell type-specific gene 14-3-3sigma. Neoplasia. 2005 Sep; 7(9):799-808. Oshiro MM, Futscher BW, Lisberg A, Wozniak RJ, Klimecki WT, Domann FE, Cress AE. PMID: 16229802; PMCID: PMC1501934.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    35. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002 Jul 04; 418(6893):41-9. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. PMID: 12077603.
      View in: PubMed   Mentions: 1458     Fields:    Translation:HumansAnimalsCells
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Aaron's Networks
    Concepts (155)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (37)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California